Pharmacokinetics of a novel trioxane antimalarial drug 99/411: alterations upon rifampicin coadministration, single and multiple oral dose drug–drug interactions in Sprague-Dawley rats. (November 2017)

• Record Type: Journal Article
• Authors: Hidau, Mahendra Kumar; Singh, Yeshwant; Singh, Shio Kumar
• Is Part Of: International journal of pharmacokinetics. Volume 2:Number 4(2017)
• Page Start: 225
• Page End: 232
• Publication Date: 2017-11
• Subjects: absorption -- accumulation -- drug interaction -- malaria -- metabolism -- parallel study -- pharmacokinetic -- relative bioavailability -- systemic exposure -- tuberculosis; Pharmacokinetics -- Periodicals; 615.705
• DOI: 10.4155/ipk-2017-0001
• Languages: English
• ISSNs: 2053-0846

Abstract

Aim: Study was aimed to investigate the potential drug–drug interactions between antimalarial candidate 99/411 and antitubercular drug rifampicin.Methods: A single-dose drug-interaction study followed by multiple dose parallel study was designed to estimate the drug–drug interactions.Results: It was found that steady-state pharmacokinetics profile of 99/411 determined after multiple dosing for five successive days was consistent with the single-dose characteristics in both the cases, when 99/411 was given alone and co-administered with rifampicin.Conclusion: The compound was absorbed fast after each dosing and declined up to next 24 h to lower concentration. AUC showed accumulation of 99/411 day by day after multiple dosing, which may affect the therapeutic response of this molecule.